GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carna Biosciences Inc (TSE:4572) » Definitions » Debt-to-Revenue

Carna Biosciences (TSE:4572) Debt-to-Revenue : 0.16 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Carna Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Carna Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円95 Mil. Carna Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円23 Mil. Carna Biosciences's annualized Revenue for the quarter that ended in Mar. 2024 was 円723 Mil. Carna Biosciences's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.16.


Carna Biosciences Debt-to-Revenue Historical Data

The historical data trend for Carna Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carna Biosciences Debt-to-Revenue Chart

Carna Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.38 0.27 0.22 0.11

Carna Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.21 0.21 0.05 0.16

Competitive Comparison of Carna Biosciences's Debt-to-Revenue

For the Biotechnology subindustry, Carna Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Debt-to-Revenue falls into.



Carna Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Carna Biosciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(126.569 + 56.402) / 1625.889
=0.11

Carna Biosciences's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(95.001 + 23.404) / 723.48
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Carna Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Carna Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Carna Biosciences (TSE:4572) Business Description

Traded in Other Exchanges
N/A
Address
BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.

Carna Biosciences (TSE:4572) Headlines

No Headlines